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T-regulator cells or myeloid-derived suppressor cells, and 
overexpression of certain ligands (e.g., programmed death 
ligand-1 [PDL-1]) that inhibit the host’s existing antitumor 
immunity. The latter effect is thought to take place by the 
cancer cells’ overexpressing ligands that can bind inhibitory 
co-receptors expressed by T lymphocytes (also known as 
“immune checkpoints”). Recent advances in melanoma 
research have led to the development of immunotherapies 
that have substantial antitumor effects in other types of 
cancer as well, including lymphoma, renal cell carcinoma, 
and non-small lung cancer (NSCLC). These advances have 
been paradigm-shifting for several reasons. For example, the 
observed immune response patterns have led to marked deep 
tumor regression that often outlasted the period of study. 
Such responses are unprecedented for disease that has been 
refractory to other types of treatment. Second, these new 
forms of immunotherapy have shown activity in tumors 
traditionally viewed as unresponsive to immune therapies, 
raising hopes that any type of cancer might be “targetable” 
by immunotherapies if the right agent can be found. This 
antitumor activity has been most impressive in NSCLC, 
particularly among patients with unresectable disease 
treated with primary radiation therapy, a modality known to 
stimulate antigen production. It is conceivable that 
treatment such as this acts as a type of “in situ vaccine” to 
prime the immune response. Nascent preclinical and early 
clinical findings have supported this possibility, suggesting 
that radiation, through its immune-stimulating properties, 
may eventually be useful as a form of systemic therapy in 
addition to a means of local tumor control. 
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Purpose: Prompt Gamma-ray Timing (PGT) is a method for 
range verification in hadron therapy which requires only 
minor or no interference with clinical routine due to a 
very low hardware footprint. The principal feasibility 
of the method for range verification has already been 
shown in theoretical considerations [1] and in proof-of-
pricipal experiments [2]. Further considerations of the 
clinical feasibility show that a high-throughput data 
acquisition system is crucial [3]. In this work, PGT 
measurements during phantom irradiation with clinical 
beam currents – both during pencil beam scanning (PBS) 
and passive beam formation (double scattering, DS) are 
presented. 
Materials and Methods: By exploiting the time structure of 
the beam on the nanosecond scale, it is possible to 
measure the duration of the emission of secondary photons. 
This duration is linked with the transit time of the 
projectiles in the target. Longer transit times reflect a 
larger range. Since no direct start signal is available, a 
classical time-of-flight measurement against the 
accelerator RF is used. Experiments were conducted at the 
University Proton Therapy Dresden (UPTD) center where 
an IBA Cyclone 230 isochronous cyclotron is installed 
with a fixed RF frequency of 106 MHz. For actual 
clinical application, it is required that the bunch width 
and phase remain constant or are monitored. The shown 
data do not incorporate any kind of bunch timing 
correction and the conditions are assumed to be 
constant. 
As a photon detector, a CeBr3  crystal in the extends of 
ø2”×1” coupled to a PMT is used. It is either read out 
with a CAEN DT5730 waveform digitizer or with a Target 
Systemelektronik U100 dedicated system which is also a 
sampling ADC based readout module. Online pulse processing 
algorithms are applied in both cases to achieve a high 
throughput rate. The ADCs were synchronized to the RF. 
Experiments during DS were conducted parasitically 
during the workflow training with an anthropomorphic 
phantom. For the PBS measurements dedicated beam time 
could be scheduled at the therapeutic treatment room. 
A rectangular dose distribution was impinged on a 
homogeneous PMMA target. In DS mode, a lead shielding 
was placed between the detector and the nozzle in 
order to reduce background radiation which originates 
from the nozzle. 
Results: In both cases, it was possible to identify the 
individual phases of beam delivery. In DS mode, the 
periodic modulation at 600 Hz which is synchronized with 
the beam formation equipment can be seen. In PBS, 
single layers and single spots can be recognized 
(figure 1). After data selection, the beam microstructure is 
revealed in PBS as well as in DS mode although it is 
considerably less clear in the DS case. 
Conclusions: The experimental techniques which are 
required for a clinical implementation of PGT are being 
evaluated under clinical beam conditions. The beam 
delivery mode has major impact on the data quality. 
 
 
 
 
 
 
 
Figure 1: Count rate over time during DS (left) and PBS 
(right), recorded at 2 Gy/min at different distances. 
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